Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Price Grouping Rule Triggered “Distortion” in Generic Market: JGA President
A new price grouping rule introduced for generic drugs last April has stirred up price competition and caused a “distortion in the market,” Japan Generic Medicines Association (JGA) President Itsuro Yoshida says. Because of the new rule, for example, some…
To read the full story
Related Article
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Gist of FY2014 NHI Price Revision
December 26, 2013
ORGANIZATION
- PhRMA Sues CMS over Medicare MFN Model, Calls It Unlawful Overreach
October 9, 2026
- Japan Generic Group Calls for Clearer Patent Extension Rules
October 9, 2026
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
- JPMA Chief Urges Manufacturing, Talent Push to Build Drug Discovery Ecosystem
October 8, 2026
- PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…